Humanization: Humanized antibodies can reduce immunogenicity, but achieving full compatibility with the human immune system ...

Their paper, “A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.

With LifeArc’s funding and scientific support, they now hope to produce a fully humanized antibody therapeutic ready for Investigative New Drug submission to the U.S. Food and Drug ...

US biotech Atossa Therapeutics (Nasdaq: ATOS) has entered into a research collaboration with China-backed Nona Biosciences, ...

2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-69.

AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and ...

Atossa Therapeutics (ATOS) announced a research collaboration with Nona Biosciences, a global biotechnology company providing integrated ...